Replimune Q2 net loss widens

Reuters

Nov 06

Replimune <a href="https://laohu8.com/S/QTWO">Q2</a> net loss widens

Overview

Replimune fiscal Q2 net loss widens to $83.1 mln from $53.1 mln last year
Cash position decreases to $323.6 mln from $483.8 mln as of March 31, 2025

Outlook

Replimune expects FDA decision on RP1 BLA by April 2026
Company plans to fund operations into late 2026

Result Drivers

R&D EXPENSES - Increase in R&D expenses due to higher costs for RP1 and RP2 studies, including IGNYTE-3
FDA ACCEPTANCE - FDA accepted BLA resubmission for RP1, potential approval progress
CLINICAL TRIAL PROGRESS - Positive data from IGNYTE trial for RP1 plus nivolumab in skin cancers

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q2 Net Income		-$83.10 mln
Q2 Basic EPS		-$0.90
Q2 Cash & Investments		$323.60 mln
Q2 Operating Expenses		$84.29 mln
Q2 Operating Income		-$84.29 mln

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Replimune Group Inc is $12.50, about 31.4% above its November 5 closing price of $8.58

Press Release: ID:nGNX8P8Bvy

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2581095871"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2581095871\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2581095871?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-06 21:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2581095871","market":"us","top_or_hot":-1,"title":"Replimune Q2 net loss widens","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Replimune <a href=\"https://laohu8.com/S/QTWO\">Q2</a> net loss widens</title></head><body><p><span>Overview</span></p><ul><li><p>Replimune fiscal Q2 net loss widens to $83.1 mln from $53.1 mln last year</p></li><li><p>Cash position decreases to $323.6 mln from $483.8 mln as of March 31, 2025</p></li></ul><p><span>Outlook</span></p><ul><li><p>Replimune expects FDA decision on RP1 BLA by April 2026</p></li><li><p>Company plans to fund operations into late 2026</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>R&amp;D EXPENSES - Increase in R&amp;D expenses due to higher costs for RP1 and RP2 studies, including IGNYTE-3</p></li><li><p>FDA ACCEPTANCE - FDA accepted BLA resubmission for RP1, potential approval progress</p></li><li><p>CLINICAL TRIAL PROGRESS - Positive data from IGNYTE trial for RP1 plus nivolumab in skin cancers</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q2 Net Income</p></td><td></td><td><p>-$83.10 mln</p></td><td></td></tr><tr><td><p>Q2 Basic EPS</p></td><td></td><td><p>-$0.90</p></td><td></td></tr><tr><td><p>Q2 Cash &amp; Investments</p></td><td></td><td><p>$323.60 mln</p></td><td></td></tr><tr><td><p>Q2 Operating Expenses</p></td><td></td><td><p>$84.29 mln</p></td><td></td></tr><tr><td><p>Q2 Operating Income</p></td><td></td><td><p>-$84.29 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 6 \"strong buy\" or \"buy\", 3 \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for Replimune Group Inc is $12.50, about 31.4% above its November 5 closing price of $8.58</p></li></ul><p>Press Release: <span>ID:nGNX8P8Bvy</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Replimune Q2 net loss widens</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nReplimune Q2 net loss widens\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-06 21:14</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Replimune <a href=\"https://laohu8.com/S/QTWO\">Q2</a> net loss widens</title></head><body><p><span>Overview</span></p><ul><li><p>Replimune fiscal Q2 net loss widens to $83.1 mln from $53.1 mln last year</p></li><li><p>Cash position decreases to $323.6 mln from $483.8 mln as of March 31, 2025</p></li></ul><p><span>Outlook</span></p><ul><li><p>Replimune expects FDA decision on RP1 BLA by April 2026</p></li><li><p>Company plans to fund operations into late 2026</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>R&amp;D EXPENSES - Increase in R&amp;D expenses due to higher costs for RP1 and RP2 studies, including IGNYTE-3</p></li><li><p>FDA ACCEPTANCE - FDA accepted BLA resubmission for RP1, potential approval progress</p></li><li><p>CLINICAL TRIAL PROGRESS - Positive data from IGNYTE trial for RP1 plus nivolumab in skin cancers</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q2 Net Income</p></td><td></td><td><p>-$83.10 mln</p></td><td></td></tr><tr><td><p>Q2 Basic EPS</p></td><td></td><td><p>-$0.90</p></td><td></td></tr><tr><td><p>Q2 Cash &amp; Investments</p></td><td></td><td><p>$323.60 mln</p></td><td></td></tr><tr><td><p>Q2 Operating Expenses</p></td><td></td><td><p>$84.29 mln</p></td><td></td></tr><tr><td><p>Q2 Operating Income</p></td><td></td><td><p>-$84.29 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 6 \"strong buy\" or \"buy\", 3 \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for Replimune Group Inc is $12.50, about 31.4% above its November 5 closing price of $8.58</p></li></ul><p>Press Release: <span>ID:nGNX8P8Bvy</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"REPL","symbol_name":"Replimune Group Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nL1N3WI0QY:1","article_id":"2581095871","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2581095871","pubTimestamp":1762434844,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Replimune Q2 net loss widensOverviewReplimune fiscal Q2 net loss widens to $83.1 mln from $53.1 mln last yearCash position decreases to $323.6 mln from $483.8 mln as of March 31, 2025OutlookReplimune ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"REPL":"Replimune Group Inc.","BK4139":"生物科技"},"translate_title":"Replimune第二季度净亏损扩大","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"REPL":0.9},"content_text":"Replimune Q2 net loss widensOverviewReplimune fiscal Q2 net loss widens to $83.1 mln from $53.1 mln last yearCash position decreases to $323.6 mln from $483.8 mln as of March 31, 2025OutlookReplimune expects FDA decision on RP1 BLA by April 2026Company plans to fund operations into late 2026Result DriversR&D EXPENSES - Increase in R&D expenses due to higher costs for RP1 and RP2 studies, including IGNYTE-3FDA ACCEPTANCE - FDA accepted BLA resubmission for RP1, potential approval progressCLINICAL TRIAL PROGRESS - Positive data from IGNYTE trial for RP1 plus nivolumab in skin cancersKey DetailsMetricBeat/MissActualConsensus EstimateQ2 Net Income-$83.10 mlnQ2 Basic EPS-$0.90Q2 Cash & Investments$323.60 mlnQ2 Operating Expenses$84.29 mlnQ2 Operating Income-$84.29 mlnAnalyst CoverageThe current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 6 \"strong buy\" or \"buy\", 3 \"hold\" and no \"sell\" or \"strong sell\"The average consensus recommendation for the biotechnology & medical research peer group is \"buy\"Wall Street's median 12-month price target for Replimune Group Inc is $12.50, about 31.4% above its November 5 closing price of $8.58Press Release: ID:nGNX8P8BvyFor questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}